Oncology

A narrative review examines EGFR P-loop/alphaC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) as structurally and clinically distinct subsets of NSCLC kinase domain alterations that show reduced sensitivity to TKIs approved for classical sensitizing mutations. The review reports that second-generation TKIs like afatinib show consistent activity against PACC variants such as G719X, S768I, E709X, and L747X, while common-plus-PACC compound mutations often respond better to third-generation TKIs including osimertinib; newer mutant-selective inhibitors firmonertinib and enozertinib are being investigated specifically for PACC mutations. For ex20ins, the review notes clinically meaningful activity with amivantamab and mutant-selective TKIs including sunvozertinib, zipalertinib, and firmonertinib, citing the WU-KONG28 trial's finding of first-line superiority of sunvozertinib over platinum-pemetrexed chemotherapy. The authors state that resistance mechanisms in both subsets remain heterogeneous, including on-target mutations such as C797S and E709K and other bypass pathways.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

A phase 3 trial (TAISHAN-302) compared tambotatug pelitecan, a B7-H3-targeting antibody-drug conjugate, with topotecan in 451 patients with small-cell lung cancer that had progressed after platinum-based therapy. The trial reported that tambotatug pelitecan resulted in significantly longer median overall survival (13.3 vs 9.4 months) and progression-free survival (7.4 vs 2.8 months), a higher objective response rate (59.1% vs 9.7%), and a lower incidence of grade 3 or higher adverse events (55.4% vs 77.9%) compared with topotecan. The findings are from a prespecified interim analysis.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

An exploratory 5-year analysis of the phase 3 KEYNOTE-826 trial (median follow-up 59.1 months) evaluated pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in 617 patients with previously untreated persistent, recurrent, or metastatic cervical cancer. The trial reported sustained overall survival benefit with pembrolizumab versus placebo in both the PD-L1 combined positive score of at least 1 group (HR, 0.62) and the intention-to-treat population (HR, 0.64), with a similarly maintained progression-free survival advantage. The authors state no new safety signals were observed and no additional treatment-related deaths occurred since the final analysis, and they characterize the findings as confirming durability of benefit for this combination as a first-line option.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

The MATTERHORN phase 3 trial evaluated perioperative durvalumab plus FLOT chemotherapy versus placebo plus FLOT in 948 patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. The trial reported a significant overall survival improvement with durvalumab (hazard ratio 0.78, 95% CI 0.63-0.96; p=0.021), building on previously reported event-free survival and pathological complete response benefits. Treatment-related deaths occurred in 6 of 475 patients on durvalumab versus 2 of 469 on placebo; the authors state this represents a new standard treatment option for this population.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.

This review examines neoadjuvant therapy options for stage II to III HER2-positive early-stage breast cancer, noting that randomized trial data indicate carboplatin can be safely omitted for most stage II patients, yielding comparable pathological complete response rates with reduced toxicity. The authors discuss de-escalation from a four-drug regimen to weekly paclitaxel with trastuzumab and pertuzumab, and biomarker-guided approaches including chemotherapy-free strategies. They also note that DESTINY-Breast11 and DESTINY-Breast05 established neoadjuvant and postneoadjuvant fam-trastuzumab deruxtecan-nxki as options for high-risk disease, both recently receiving FDA approval, and propose a framework incorporating circulating tumor DNA monitoring and functional imaging as priorities for future study.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.